-+ 0.00%
-+ 0.00%
-+ 0.00%
12 Health Care Stocks Moving In Monday's After-Market Session
Share
Listen to the news

Gainers

  • Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million.
  • Eocene (NASDAQ:EOCN) shares rose 10.65% to $4.05. The market value of their outstanding shares is at $4.1 million.
  • Baird Medical Investment (NASDAQ:BDMD) stock moved upwards by 9.43% to $1.16. The company's market cap stands at $35.1 million.
  • Creative Medical Tech (NASDAQ:CELZ) shares rose 5.23% to $0.92. The market value of their outstanding shares is at $6.3 million.
  • Basel Medical Group (NASDAQ:BMGL) shares increased by 5.0% to $7.5.
  • iBio (NASDAQ:IBIO) shares rose 5.0% to $1.26. The market value of their outstanding shares is at $77.4 million.

Losers

  • Bio Green Med Solution (NASDAQ:BGMS) stock fell 10.9% to $0.8 during Monday's after-market session. The market value of their outstanding shares is at $5.7 million.
  • Kestra Medical Techs (NASDAQ:KMTS) stock decreased by 9.61% to $21.75. The market value of their outstanding shares is at $1.3 billion. As per the press release, Q1 earnings came out today.
  • Aclaris Therapeutics (NASDAQ:ACRS) shares fell 9.24% to $5.12. The company's market cap stands at $783.0 million.
  • Armata Pharmaceuticals (AMEX:ARMP) shares decreased by 9.19% to $5.04. The market value of their outstanding shares is at $200.0 million.
  • Radiopharm Theranostics (NASDAQ:RADX) shares declined by 7.47% to $1.86. The company's market cap stands at $28.6 million.
  • Lexaria Bioscience (NASDAQ:LEXX) shares fell 6.48% to $3.32. The company's market cap stands at $8.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending